AAV hybrid serotypes: improved vectors for gene delivery - Wikidata - awgldk - TriplyDB

AAV hybrid serotypes: improved vectors for gene delivery

AAV hybrid serotypes: improved vectors for gene delivery

http://www.wikidata.org/entity/Q34619573

about

Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain Morquio A syndrome: diagnosis and current and future therapies Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells.Interior engineering of a viral nanoparticle and its tumor homing properties.In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles.Efficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates.Establishment of an AAV reverse infection-based array.Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS Gene therapy for inherited muscle diseases: where genetics meets rehabilitation medicine.Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6 Recombinant AAV-directed gene therapy for type I glycogen storage diseases.Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates Host cell DNA repair pathways in adeno-associated viral genome processing Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes.Perspectives on the use of gene therapy for chronic joint diseases.Enhancing gene delivery of adeno-associated viruses by cell-permeable peptides Adeno-associated virus type 2 vectors: transduction and long-term expression in cerebellar Purkinje cells in vivo is mediated by the fibroblast growth factor receptor 1 : bFGFR-1 mediates AAV2 transduction of Purkinje cells.Notch1 augments intracellular trafficking of adeno-associated virus type 2.Vectored antibody gene delivery for the prevention or treatment of HIV infection.Methods for gene transfer to the central nervous system.The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.New vectors and strategies for cardiovascular gene therapy.Gene therapy progress and prospects--vectorology: design and production of expression cassettes in AAV vectors.Nanoparticle-motivated gene delivery for ophthalmic application Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype The use of recombinant adeno-associated virus for skeletal gene therapy.The neostriatum: two entities, one structure?Gene therapy for type I glycogen storage diseases Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6 Adeno-associated viral vectors show serotype specific transduction of equine joint tissue explants and cultured monolayers The state of the art of adeno-associated virus-based vectors in gene therapy.Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo GPR30 differentially regulates short latency responses of luteinising hormone and prolactin secretion to oestradiol Selection and evaluation of clinically relevant AAV variants in a xenograft liver model.

P2860

Q26770355-95D527FC-CF32-4316-9461-307FCB330D6D Q27014063-B38068C7-0FB1-4005-B950-08765D0E9A6A Q27349992-E2A9A385-6227-463E-8F4F-54326E240322 Q27679952-92CBF030-B454-4C1D-A00A-420C678B2257 Q30500177-5803E21D-5642-409C-8D9A-1C77F0D4CFAB Q30530235-933B77EE-A582-44E8-AB00-EF8339B86BA3 Q33327474-0E9E45AA-1CF1-40F0-847A-456084115C7F Q33337378-D3AE5642-F31A-421D-889B-7DF414237C18 Q33713355-CD38DC1E-58A8-4F64-86FA-C9B4C0DBB3ED Q33728191-D16A27DB-300B-4111-AD13-EB3421F1A020 Q33894621-F0D94715-270F-4E5D-B2DC-47F6ECDE0E4E Q34340857-753EFD4A-767A-4537-BACC-A98B52B8FBA7 Q34545883-8A59DEF4-EDFD-4EA3-ABC2-15B4BD2198F1 Q35024289-773C6913-18D2-40D2-BD34-57BFB6B8D44B Q35078590-08F296BC-5C33-4EEF-AFA1-0CACAA875DA5 Q35094530-F38F4F96-C215-4AC0-9924-673CCCE59381 Q35139314-AFDAEF33-9379-418F-867F-69FB2C9C16AC Q35139648-CC31C045-9D5B-49EE-9148-850C4E8576F4 Q35151031-0B82C8B1-6D43-45A9-8936-09915C3680D6 Q35194907-8E355E66-FBB4-42D2-936B-41306C65BECC Q35362227-CC5E8554-143A-4C9C-A2FA-0C2B3929BD5D Q35635454-B1644BF5-2A6F-424C-ABD7-F5CCB7ADDF45 Q35664155-A7F99098-7151-4E64-B68A-2B620C5D7A1D Q35902332-2024234F-A8A4-42B6-AAA0-133C728C31F9 Q36155013-71365B45-A18F-4D52-911A-9B727BF2AA24 Q36174173-5BAC397C-3937-4507-88CC-049D0A79EEB2 Q36384464-141395E3-B66A-4D4A-8F99-38DD829B5AAE Q36396201-D61E58BB-1157-4F4F-A6CF-26260584408F Q36508670-B3C02D29-8E5B-4D93-8F61-FABF40C0F7EE Q36715338-32DDC98D-8137-46A6-AAEE-FFBC9283455C Q36729692-E5650FEB-6418-4B13-AEF0-4ACC6AB1181B Q36762445-862D9058-65B7-4F2C-9719-64470581ADA2 Q36789527-896AE29A-8529-46AD-841F-F263C18D2DE4 Q36968803-74C096E3-633C-4EF2-A27F-77A5CFE4A4F0 Q36972596-709D0677-94C1-49BC-B9B0-0C78CC33883D Q36972714-81000D6B-360C-42C9-BAD8-B9A09C03F9D1 Q37066323-26778496-8D71-478B-B1A7-A38FB073703B Q37066326-EBE71B5F-D56E-46AB-8CD4-1AF919C70D86 Q37373591-5BD366D3-8010-44AC-BB7F-AAAE60B66983 Q37610916-353BF044-735B-4944-89A7-74C10EE2D5D8

P2860

AAV hybrid serotypes: improved vectors for gene delivery

http://www.wikidata.org/entity/Q34619573

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

AAV hybrid serotypes: improved vectors for gene delivery

@ast

AAV hybrid serotypes: improved vectors for gene delivery

@en

AAV hybrid serotypes: improved vectors for gene delivery

@nl

type

label

AAV hybrid serotypes: improved vectors for gene delivery

@ast

AAV hybrid serotypes: improved vectors for gene delivery

@en

AAV hybrid serotypes: improved vectors for gene delivery

@nl

prefLabel

AAV hybrid serotypes: improved vectors for gene delivery

@ast

AAV hybrid serotypes: improved vectors for gene delivery

@en

AAV hybrid serotypes: improved vectors for gene delivery

@nl

P1433

Q34619573-D3D7B88D-37CA-45A9-BA68-AE6787F04FB0

P1476

Q34619573-C0C3E5C2-9678-446E-BEC1-0CE03FF51B9D

P2093

Q34619573-110BE67D-62C2-4582-8029-8AB69CEA11E1

Q34619573-7623FD3E-FB8E-4440-B735-715CDA84EB8C

Q34619573-84F3CF8E-872A-4813-9C66-7B75DB9F2217

P2860

Q34619573-090940EF-6C81-464C-BDDB-C82F0A918521

Q34619573-093AF5AB-BA49-43AF-B9FD-5FAB5031E807

Q34619573-0A4DEC6F-81D7-4E97-90A5-FEF9FCE378E6

Q34619573-0B265AAA-260F-461F-ABDD-85F06BA2B9C3

Q34619573-0DFEE86A-4E21-4764-AA0B-5939B86A1A79

Q34619573-0EC62739-C3AD-4140-A7FA-497CBA73C267

Q34619573-0F0DA5F3-9E96-4184-ACD4-A98971C51B37

Q34619573-11275ED8-4498-4B56-9D5B-4E326002C51F

Q34619573-13555F9D-8C19-4627-9507-1873C48DE5CC

Q34619573-169024BA-278F-497F-AE30-A35FD97E556E

P304

Q34619573-0740FEC7-BBF3-4C8E-9FE2-D4FC3FEF9DF7

P31

Q34619573-8F0C5AF5-6F32-499B-AC61-08A0D5FA904F

P356

Q34619573-0B680032-B246-4BB9-8B3A-D548B08A5773

P407

Q34619573-AA154CA0-542C-45CC-BE8C-47FBE1B86487

P433

Q34619573-370A9B99-3B01-47C4-B82F-55B7C9EF1E56

P478

Q34619573-23D08B0C-8333-4714-8861-3AA3A0860702

P577

Q34619573-86B1DFCB-B77D-4BED-9EBF-9F745C02633E

P5875

Q34619573-06A8A0BC-D4AF-44C9-A476-84A5C56B3C86

P698

Q34619573-ADA8DB79-2AD5-4FA8-A135-65C71E49632F

P932

Q34619573-F008FF55-4C43-446F-AF8D-561F8BB36087

P356

1566523054064968

P1433

Current Gene Therapy

P1476

AAV hybrid serotypes: improved vectors for gene delivery

@en

P2093

Douglas M McCarty

http://www.w3.org/2001/XMLSchema#string

R Jude Samulski

http://www.w3.org/2001/XMLSchema#string

Vivian W Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.

Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus

Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups

Structure determination of feline panleukopenia virus empty particles

The structure of an insect parvovirus (Galleria mellonella densovirus) at 3.7 A resolution

ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES

P304

299-310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1566523054064968

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7768697

http://www.w3.org/2001/XMLSchema#string

P698

15975007

http://www.w3.org/2001/XMLSchema#string

P932

1462937

http://www.w3.org/2001/XMLSchema#string